Cantor Fitzgerald Investment Advisors L.P. Sells 4,065 Shares of Organon & Co. (NYSE:OGN)

Cantor Fitzgerald Investment Advisors L.P. trimmed its holdings in shares of Organon & Co. (NYSE:OGN) by 3.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,498 shares of the company’s stock after selling 4,065 shares during the period. Cantor Fitzgerald Investment Advisors L.P.’s holdings in Organon & Co. were worth $1,843,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the business. Prospera Private Wealth LLC bought a new position in shares of Organon & Co. during the third quarter valued at approximately $25,000. Horizon Bancorp Inc. IN boosted its position in Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after acquiring an additional 1,585 shares in the last quarter. Versant Capital Management Inc increased its holdings in shares of Organon & Co. by 92.2% in the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock valued at $41,000 after acquiring an additional 1,324 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Organon & Co. by 32.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after purchasing an additional 672 shares during the last quarter. Finally, Abich Financial Wealth Management LLC boosted its position in Organon & Co. by 5,646.3% during the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock valued at $45,000 after purchasing an additional 2,315 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Down 1.7 %

Organon & Co. stock opened at $14.63 on Friday. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10. The business has a fifty day moving average price of $15.37 and a 200-day moving average price of $17.72. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The stock has a market capitalization of $3.77 billion, a price-to-earnings ratio of 2.90, a PEG ratio of 0.83 and a beta of 0.76.

Analyst Upgrades and Downgrades

Separately, TD Cowen raised shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $21.33.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.